Noveome Biotherapeutics has signed a commercial license agreement for the use of SipNose’s intranasal Cribriform Targeted Device (CT6) for delivery of its ST266 secretome for the treatment of ophthalmological and CNS conditions the companies said. Noveome has been working with SipNose since 2015 and used the device in a Phase 1 trial of ST266 for optic nerve disease that was initiated in 2019. Earlier this year, Noveome partnered with the Walter Reed Army Institute of Research to evaluate the potential of intranasal ST266 for the treatment of traumatic brain injury.
Noveome Founder and Chairman of the Board William J. Golden commented, “Noveome and SipNose have established a great working relationship which has enabled a successful collaboration. Noveome recently closed enrollment and completed the treatment phase of its Phase 1 safety study using the SipNose device to administer ST266 to glaucoma suspect patients. Safety analyses are underway and are expected to be announced soon. Once we have established the safety of ST266 by this novel route of administration, we plan to execute on the vast potential of our cell-free platform biologic in a variety of neurological and ophthalmological indications.”
SipNose Co-Founder and CEO Iris Shichor said, “This agreement represents a breakthrough in the area of non-invasive direct nose to brain delivery resulting from our intensive collaboration over the past 5 years. We are proud to collaborate with Noveome and to promote the use of their biologic ST266 with our proprietary delivery technology for the benefit of patients suffering from ophthalmological and neurological conditions.”
Read the Noveome Biotherapeutics and SipNose press release.
